Platelet-Rich Plasma Therapy for Pyoderma
What You Need to Know Before You Apply
What is the purpose of this trial?
Pyoderma gangrenosum (PG) is a chronic inflammatory condition with severe painful ulcers. We hypothesize that Platelet-rich plasma(PRP) therapy derived from patient's own blood has a high concentration of endogenous growth factors, which will activate the wound-healing cascade stimulating formation of new blood vessels and collagen in PG ulcers.The goal of this study is to evaluate the efficacy and safety of autologous Platelet rich Plasma(PRP) therapy for the treatment of chronic Pyoderma Gangrenosum(PG). Researchers will also compare the efficacy of PRP therapy when used as a topical solution versus injections in and around the target ulcer/s.
Will I have to stop taking my current medications?
The trial requires that you do not change your dose of immunosuppressive medications or biologics within 2 months before starting the study. Systemic corticosteroids should not exceed 20 mg per day and should not be increased during the trial. Other treatments should be kept stable throughout the study.
Is Platelet-Rich Plasma Therapy generally safe for humans?
How is Platelet-Rich Plasma Therapy different from other treatments for pyoderma?
Platelet-Rich Plasma Therapy is unique because it uses a patient's own blood components to promote healing, which may reduce the risk of adverse reactions compared to traditional treatments like immunosuppressive drugs or steroids. Unlike other therapies that focus on reducing inflammation or infection, PRP Therapy aims to enhance the body's natural healing processes by concentrating growth factors at the wound site.678910
What data supports the effectiveness of the treatment Platelet-Rich Plasma Therapy for Pyoderma?
Who Is on the Research Team?
Benjamin H. Kaffenberger, MD
Principal Investigator
The Ohio State University- Dermatology
Are You a Good Fit for This Trial?
This trial is for adults with a confirmed diagnosis of Pyoderma Gangrenosum (PG), characterized by painful skin ulcers. Participants must have a specific severity score, at least two qualifying ulcers, and no pregnancy if applicable. They should not be part of any other PG study and must consent to the trial's procedures.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either intralesional PRP injections or topical PRP therapy at 0, 4, 8, and 12 weeks, with a third group receiving standard wound care only
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Platelet-Rich Plasma Therapy
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ohio State University
Lead Sponsor